Mrtx0902 | 2654743-22-1

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: Mrtx0902
• 英文别名: 2-methyl-3-[(1R)-1-[(4-methyl-7-morpholin-4-ylpyrido[3,4-d]pyridazin-1-yl)amino]ethyl]benzonitrile
• CAS: 2654743-22-1
• 化学式: C₂₂H₂₄N₆O
• 分子量: 388.5
• InChiKey: ILPWEAHQRAWJIU-OAHLLOKOSA-N

物化性质

• 沸点：
  658.0±55.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO:125.0(最大浓度 mg/mL);321.77(最大浓度 mM)

计算性质

• 辛醇/水分配系数(LogP)：
  3.52
• 重原子数：
  29.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  86.96
• 氢给体数：
  1.0
• 氢受体数：
  7.0

文献信息

• SOS1 INHIBITORS
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210188857A1

  公开（公告）日：2021-06-24

  The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
• COMBINATION THERAPIES
  申请人：Mirati Therapeutics, Inc.

  公开号：US20220395507A1

  公开（公告）日：2022-12-15

  The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRas G12C inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.
• [EN] FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS<br/>[FR] COMPOSÉS HÉTÉROARYLE FUSIONNÉS UTILES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：[en]KUMQUAT BIOSCIENCES INC.

  公开号：WO2022266015A1

  公开（公告）日：2022-12-22

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.